Revenues for the second quarter ended June 30 , 2009 were $ 3.0 million , up from $ 2.7 million for the corresponding period in 2008 . The increase was primarily attributable to $ 272,000 of grant revenue related to the IPLEX ( TM ) myotonic muscular dystrophy ( " MMD " ) clinical trial recorded in the most recent second quarter .